ProstaLund AB (PLUN) AI Stock Analysis

• Market Cap: €3.88M
• Dividend Yield: N/A
• Average Volume (3M): 38.56K
• Price to Earnings (P/E): ―
• Beta (1Y): <0.01
• Revenue Growth: -30.56%
• EPS Growth: 7.17%
• Country: SE
• Employees: 9
• Sector: Healthcare
• Sector Strength: 44
• Industry: Medical - Care Facilities
• EPS (TTM): -1.39
• Shares Outstanding: 3,624,052
• 10 Day Avg. Volume: 18,455
• 30 Day Avg. Volume: 38,556
• PEG Ratio: -32.37
• Price to Book (P/B): 206.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -410.80
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 42 Neutral
• Price Target: kr1.00 ▼(-3.85%Downside)

ProstaLund AB's overall stock score is impacted most significantly by its financial performance, which highlights declining revenues, persistent losses, and cash flow issues. Technical analysis further supports a bearish outlook with weak momentum indicators. Valuation metrics underscore the company's challenges with a negative P/E ratio and lack of dividend yield, making it a risky investment.

ProstaLund AB Business Overview & Revenue Model

Company Description

ProstaLund AB is a Swedish medical technology company operating in the healthcare sector. The company specializes in developing and commercializing innovative products and solutions for minimally invasive treatment of benign prostatic hyperplasia (BPH). Its flagship product, the CoreTherm system, utilizes a proprietary technology for thermal treatment of BPH, offering patients an effective alternative to surgical procedures.

How the Company Makes Money

ProstaLund AB generates revenue primarily through the sale and distribution of its CoreTherm system, which is used by healthcare providers for treating patients with benign prostatic hyperplasia. The company also earns money from service agreements and maintenance contracts related to its equipment. Key revenue streams include direct sales to hospitals and clinics, as well as partnerships with distributors and healthcare organizations. Additionally, ProstaLund may derive income from training services and support provided to medical professionals using its technology.

ProstaLund AB Financial Statement Overview

Summary

ProstaLund AB faces challenges with declining revenues and persistent losses impacting both profitability and cash flow. While the balance sheet remains relatively stable, cash flow issues and negative earnings signal potential financial instability if not addressed.

Income Statement

ProstaLund AB shows a declining revenue trend with significant negative EBIT and net income over the past years, indicating operational inefficiencies. The gross profit margin is positive but overshadowed by increasing operating losses, affecting overall profitability.

Balance Sheet

The company maintains a solid equity base with manageable debt levels, as reflected in a low debt-to-equity ratio. However, the consistent net losses are eroding equity, posing risks if the trend persists.

Cash Flow

Negative operating and free cash flows highlight cash burn issues, indicating ProstaLund AB is relying heavily on financing activities to sustain operations. The inability to generate positive cash flow from operations is concerning for long-term sustainability.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
13.72M	22.21M	17.41M	17.07M	12.46M
	Gross Profit
8.87M	15.65M	12.87M	14.68M	9.54M
	EBIT
-22.49M	-16.85M	-10.89M	-7.86M	-9.92M
	EBITDA
-22.45M	-16.57M	-10.67M	-7.54M	-9.75M
	Net Income Common Stockholders
-22.63M	-17.01M	-11.30M	-7.92M	-10.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
7.82M	15.35M	12.28M	13.24M	10.49M
	Total Assets
61.64M	65.51M	51.04M	43.48M	30.84M
	Total Debt
933.00K	1.33M	1.73M	200.00K	600.00K
	Net Debt
-6.89M	-14.02M	-10.54M	-13.04M	-9.89M
	Total Liabilities
6.46M	10.22M	9.36M	8.02M	5.49M
	Stockholders Equity
55.18M	55.29M	41.69M	35.46M	25.35M
Cash Flow		Free Cash Flow
-29.58M	-27.06M	-20.96M	-14.99M	-12.05M
	Operating Cash Flow
-22.59M	-23.80M	-16.20M	-5.80M	-8.58M
	Investing Cash Flow
-6.99M	-3.35M	-4.75M	-9.19M	-3.47M
	Financing Cash Flow
22.37M	30.22M	19.99M	17.73M	12.79M

ProstaLund AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:PLUN, the sentiment is Negative. The current price of 1.04 is below the 20-day moving average (MA) of 1.37, below the 50-day MA of 4.74, and below the 200-day MA of 8.74, indicating a bearish trend. The MACD of -1.09 indicates Negative momentum. The RSI at 22.01 is Positive, neither overbought nor oversold. The STOCH value of 42.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:PLUN.

ProstaLund AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMOTEC.B	54 Neutral	kr44.70M	―	-236.60%	―	132.67%	58.89%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
PLUN	42 Neutral	€3.88M	―	-44.57%	―	-30.56%	7.17%
LIDDS	37 Underperform	kr5.46M	―	-107.11%	―	―	94.98%
PROGEN	35 Underperform	kr41.23M	―	-139.61%	―	-85.32%	92.64%
ACTI	32 Underperform	€283.55M	―	-186.40%	―	―	24.47%